{ "schemaVersion": 1, "organisationId": "O-7a5ceb0b90214ab7b983ccb0100c8e43", "slug": "regeneron-pharmaceuticals", "name": "REGENERON PHARMACEUTICALS, INC.", "updatedAt": "2026-03-19T03:51:55.907043Z", "sections": [ { "type": "OVERVIEW", "text": "Regeneron Pharmaceuticals, Inc. is a biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It is a fully integrated company that invents, develops, manufactures, and commercializes medicines for people with serious diseases, with products and research programs spanning eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.[https://www.regeneron.com/about/history][https://careers.regeneron.com/en/locations/north-america/westchester/][P-ab5737ec026247e4a603b9aa673ddbcb] Regeneron describes its mission as using the power of science to bring new medicines to patients “over and over again.”[https://www.regeneron.com/about/our-company]\n\nThe company operates as a science-led, multi-product biotech, combining research, clinical development, manufacturing, and commercialization capabilities, and its business is defined by products such as EYLEA HD/EYLEA, Dupixent, and Libtayo.[P-b26b726a18cc484bb5bdf62b9bf64d0a][T-124a424955cb40f4b2a3fd4a898aa490] Regeneron commercializes some products directly and relies on major collaborators such as Bayer and Sanofi for parts of its global reach; it has also built certain commercial capabilities outside the United States and manufactures products in New York and Ireland.[P-1e0226095a2b49bfbc079a265c1b82b6][P-11f3fd3688d24aa08c6307571d97e1f1][P-ec6c269b8c6745369863a6c0165a85b6] As a size indicator, Regeneron reported $14.20 billion in revenue for 2024 and had 15,106 full-time employees at year-end, with most employees in the United States and additional concentrations in Ireland and other countries.[P-a0aecc7a10f74963b2ce9c8330a7d05d][P-a193603d23204e69a696d68db309612d]\n[P-ab5737ec026247e4a603b9aa673ddbcb][P-b26b726a18cc484bb5bdf62b9bf64d0a][T-124a424955cb40f4b2a3fd4a898aa490][P-1e0226095a2b49bfbc079a265c1b82b6][P-11f3fd3688d24aa08c6307571d97e1f1][P-ec6c269b8c6745369863a6c0165a85b6][P-a0aecc7a10f74963b2ce9c8330a7d05d][P-a193603d23204e69a696d68db309612d][https://www.regeneron.com/about/history][https://careers.regeneron.com/en/locations/north-america/westchester/][https://www.regeneron.com/about/our-company]", "updatedAt": "2026-03-19T03:51:55.907043Z" }, { "type": "PRODUCTS", "text": "Regeneron’s commercial portfolio is led by the aflibercept franchise. EYLEA HD is described as a soluble fusion protein and VEGF inhibitor that blocks VEGF-A and placental growth factor (PLGF), and it is approved for wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; EYLEA is approved for those retinal diseases plus macular edema following retinal vein occlusion, myopic choroidal neovascularization, neovascular glaucoma, and retinopathy of prematurity. In 2024, EYLEA HD generated $1.20 billion and EYLEA generated $4.77 billion of U.S. net product sales, and together the two products represented 42% of Regeneron’s total revenue. [P-b383fd03f62d4786a93f5e2a66a2d74d][T-6f091f9c7dc9486c81148155a7e80202][T-84ac0a4b0a5b46379be6646a431c979c][P-bdd8837041e54718a1018dedbad14db0]\n\nIn oncology, Libtayo (cemiplimab) is a fully human monoclonal antibody targeting the PD-1 immune checkpoint receptor on T cells and is marketed for several cancers including non-small cell lung cancer, basal cell carcinoma, cutaneous squamous cell carcinoma, and cervical cancer; it generated $1.22 billion in 2024, equal to 8.6% of total revenue. Praluent (alirocumab) is a fully human monoclonal antibody that inhibits PCSK9 binding to the LDL receptor to lower LDL cholesterol, and Regeneron also markets Evkeeza for homozygous familial hypercholesterolemia and Inmazeb for infection caused by Zaire ebolavirus. The company’s newer marketed products also include Ordspono (odronextamab), a bispecific monoclonal antibody designed to bridge CD20 on cancer cells with CD3-expressing T cells, for follicular lymphoma and diffuse large B-cell lymphoma, and Veopoz (pozelimab), a fully human monoclonal antibody that blocks complement factor C5, for CHAPLE. [P-d380cf0de72d4edd877335946ea6f907][T-216cefd3c4f44bb78e58e058ea26d4a5][T-84ac0a4b0a5b46379be6646a431c979c][P-c9ce9efee6ef496ca838ae8fd7680b73][P-0283b6d8812c4b4e8a48879c5bdd68c6][P-0bcd5d0141a24e1eb020da0c8cbd1ead][P-ba69a7b89bca4760b7bb8fcb7bc4fd46][P-51916bd12b7a4a2a9d4f729be0e594cc]\n\nRegeneron also participates in major co-commercialized products through collaborations. Dupixent is a fully human monoclonal antibody that inhibits IL-4 and IL-13 signaling for atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, COPD, eosinophilic esophagitis, prurigo nodularis, and chronic spontaneous urticaria, while Kevzara binds the IL-6 receptor for rheumatoid arthritis, polymyalgia rheumatica, and polyarticular juvenile idiopathic arthritis; Sanofi records the global net product sales for both products and Regeneron records its share of profits in collaboration revenue rather than net product sales. Regeneron also supplies clinical and commercial bulk product for EYLEA HD and EYLEA outside the United States under its Bayer collaboration and records reimbursement for manufacturing ex-U.S. commercial supplies; Bayer collaboration revenue was $1.50 billion in 2024, with Regeneron’s share of profits equal to 39% of ex-U.S. EYLEA 8 mg/EYLEA net product sales. The company’s product capabilities are built on Trap technology, which generated EYLEA HD and EYLEA, and the VelociSuite platform, which is used to discover and produce fully human antibodies and bispecific antibodies. [P-2363abb923304d9f94252a9746605e87][P-3e3363d559e242baa9b4ad1f59578ae6][T-216cefd3c4f44bb78e58e058ea26d4a5][T-124a424955cb40f4b2a3fd4a898aa490][P-f821ca0a59c94e42ae46c62681632ad2][T-653a90703bd44eb38a55c652cee530d4][T-500cb8cb797c4a2a9bb55ede4323943a][T-84ac0a4b0a5b46379be6646a431c979c][P-688c9b6a47ab4502bcce9d4811a486bb][P-304512c7a1c645088a62de029e7efe8a]\n[P-b383fd03f62d4786a93f5e2a66a2d74d][T-6f091f9c7dc9486c81148155a7e80202][T-84ac0a4b0a5b46379be6646a431c979c][P-bdd8837041e54718a1018dedbad14db0][P-d380cf0de72d4edd877335946ea6f907][T-216cefd3c4f44bb78e58e058ea26d4a5][P-c9ce9efee6ef496ca838ae8fd7680b73][P-0283b6d8812c4b4e8a48879c5bdd68c6][P-0bcd5d0141a24e1eb020da0c8cbd1ead][P-ba69a7b89bca4760b7bb8fcb7bc4fd46][P-51916bd12b7a4a2a9d4f729be0e594cc][P-2363abb923304d9f94252a9746605e87][P-3e3363d559e242baa9b4ad1f59578ae6][T-124a424955cb40f4b2a3fd4a898aa490][P-f821ca0a59c94e42ae46c62681632ad2][T-653a90703bd44eb38a55c652cee530d4][T-500cb8cb797c4a2a9bb55ede4323943a][P-688c9b6a47ab4502bcce9d4811a486bb][P-304512c7a1c645088a62de029e7efe8a]", "updatedAt": "2026-03-19T03:51:55.907043Z" }, { "type": "GEOGRAPHY", "text": "Regeneron’s geographic footprint is centered on the United States and Ireland. Its principal executive offices are in Tarrytown, New York, and its main owned and leased properties include corporate headquarters, laboratory, and office space in Tarrytown; manufacturing, warehouse, laboratory, fill/finish, and office space in Rensselaer, New York; and manufacturing, warehouse, laboratory, and office space in Limerick, Ireland. The company also states that it has offices in the United Kingdom, Germany, Japan, and other countries outside the United States. [P-f77933f52de041649ee8720c6a1a6116][P-3f1ee0b9ce51442981748bc5cb276e6d][P-245e0846cd974437b6bb0e3c03f0a029]\n\nIts manufacturing base is split between New York and Ireland: Regeneron says it manufactures bulk drug materials and products in Rensselaer and Limerick, with approximately 100,000 liters of cell culture capacity in Rensselaer and 120,000 liters in Limerick. It also owns an approximately 100-acre parcel adjacent to Tarrytown for future expansion and acquired an approximately 1,000,000-square-foot facility in Saratoga Springs, New York in 2024. [P-ec6c269b8c6745369863a6c0165a85b6][P-efb7934e5c6b4c5d92d8dcbe283c2973][P-dd9b7eabf30b4452b17b9c9c8473daed]\n\nThe workforce is also concentrated in these geographies. As of December 31, 2024, Regeneron had 15,106 full-time employees, including 11,914 in the United States, 2,168 in Ireland, and 1,024 in other countries, primarily the United Kingdom, Japan, and Germany. [P-a193603d23204e69a696d68db309612d]\n\nSales are weighted toward the U.S. market, although the company has a meaningful rest-of-world business. For 2024, the company’s net product sales table shows $17.869 billion in the United States and $8.567 billion in the rest of world, which is roughly a 68%/32% split; this table relates to net product sales rather than total company revenue. [T-124a424955cb40f4b2a3fd4a898aa490][P-623293aafd8e412799fd048eedbb74ce]\n[P-f77933f52de041649ee8720c6a1a6116][P-3f1ee0b9ce51442981748bc5cb276e6d][P-245e0846cd974437b6bb0e3c03f0a029][P-ec6c269b8c6745369863a6c0165a85b6][P-efb7934e5c6b4c5d92d8dcbe283c2973][P-dd9b7eabf30b4452b17b9c9c8473daed][P-a193603d23204e69a696d68db309612d][T-124a424955cb40f4b2a3fd4a898aa490][P-623293aafd8e412799fd048eedbb74ce]", "updatedAt": "2026-03-19T03:51:55.907043Z" }, { "type": "SEGMENTS", "text": "Regeneron Pharmaceuticals reports a single operating and reportable segment. The company states that it manages the business as one segment covering all activities related to the discovery, development, and commercialization of medicines for serious diseases, so its official segment contribution is effectively 100% in one segment rather than split across multiple reportable business lines.[P-6a6f1881e3fe4b35ac2dafe9a39727c1]\n\nBecause there is no formal multi-segment reporting, the main disclosed economic breakdown is by revenue stream. In 2024, net product sales were $7.63 billion, or about 53.7% of total revenue; collaboration revenue was $6.06 billion, or about 42.7%; and other revenue was $515 million, or about 3.6%.[T-84ac0a4b0a5b46379be6646a431c979c] Within Regeneron-recorded net product sales, the EYLEA HD/EYLEA U.S. franchise contributed about 78.2%, Libtayo about 16.0%, Praluent about 3.2%, Evkeeza about 1.6%, and Inmazeb about 1.0% in 2024.[T-84ac0a4b0a5b46379be6646a431c979c] Within collaboration revenue, Sanofi represented about 74.8% of the total, Bayer about 24.7%, and Roche and other items were collectively less than 1%.[T-84ac0a4b0a5b46379be6646a431c979c]\n\nRegeneron also provides a separate product/commercialization view for Regeneron-discovered products, which is not a reportable segment disclosure but shows how commercialization is split between Regeneron and partners. In 2024, this table showed EYLEA HD/EYLEA at $9.55 billion globally, with U.S. sales recorded by Regeneron and ex-U.S. sales recorded by Bayer; Dupixent at $14.15 billion globally and Kevzara at $459 million globally, both recorded by Sanofi; Libtayo at $1.22 billion globally, recorded by Regeneron; Praluent at $765 million globally, with U.S. sales recorded by Regeneron and ex-U.S. sales recorded by Sanofi; and REGEN-COV at $3.5 million, recorded outside the U.S. by Roche.[P-301962b5c4be4e2f86f69867ba46a0c1][T-124a424955cb40f4b2a3fd4a898aa490]\n[P-6a6f1881e3fe4b35ac2dafe9a39727c1][T-84ac0a4b0a5b46379be6646a431c979c][P-301962b5c4be4e2f86f69867ba46a0c1][T-124a424955cb40f4b2a3fd4a898aa490]", "updatedAt": "2026-03-19T03:51:55.907043Z" }, { "type": "HISTORY", "text": "Regeneron Pharmaceuticals was founded in 1988 by Leonard S. Schleifer, with George D. Yancopoulos as co-founder; the company was incorporated in New York that year and became publicly listed in 1991.[https://www.regeneron.com/about/leadership/leonard-schleifer][https://www.regeneron.com/about/leadership/george-yancopoulos][P-836f4ece174444118b4062d9bd6290a3] In 2007, Regeneron entered a global strategic collaboration with Sanofi, which was later amended in 2015 and expanded to include immuno-oncology work.[P-c8fe1cd47a2748a085c31166567fee79]\n\nA major commercial milestone came in 2008, when ARCALYST became Regeneron’s first FDA-approved product.[https://investor.regeneron.com/news-releases/news-release-details/fda-approves-regenerons-arcalysttm-rilonacept-treatment/] The company then broadened its product base with the FDA approval of EYLEA in 2011, Dupixent in 2017, and Libtayo in 2018, marking important expansion into ophthalmology, immunology, and oncology.[https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-fda-approval-eylear-aflibercept-injection/][P-75109b916d9d45e98c752dc56bd807c4][P-e0840901e8024776bfaa685b424252e2]\n[P-836f4ece174444118b4062d9bd6290a3][P-c8fe1cd47a2748a085c31166567fee79][P-75109b916d9d45e98c752dc56bd807c4][P-e0840901e8024776bfaa685b424252e2][https://www.regeneron.com/about/leadership/leonard-schleifer][https://www.regeneron.com/about/leadership/george-yancopoulos][https://investor.regeneron.com/news-releases/news-release-details/fda-approves-regenerons-arcalysttm-rilonacept-treatment/][https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-fda-approval-eylear-aflibercept-injection/]", "updatedAt": "2026-03-19T03:51:55.907043Z" } ], "sources": [ { "id": "https://www.regeneron.com/about/history", "href": "https://www.regeneron.com/about/history", "label": "www.regeneron.com" }, { "id": "https://careers.regeneron.com/en/locations/north-america/westchester/", "href": "https://careers.regeneron.com/en/locations/north-america/westchester/", "label": "careers.regeneron.com" }, { "id": "P-ab5737ec026247e4a603b9aa673ddbcb", "href": "https://app.finbar.com/go?id=P-ab5737ec026247e4a603b9aa673ddbcb", "label": "REGENERON PHARMACEUTICALS, INC. — Full financial report (2024 Y)", "documentId": "D-dff46eb0bec646559714d5350deb456d" }, { "id": "https://www.regeneron.com/about/our-company", "href": "https://www.regeneron.com/about/our-company", "label": "www.regeneron.com" }, { "id": "P-b26b726a18cc484bb5bdf62b9bf64d0a", "href": "https://app.finbar.com/go?id=P-b26b726a18cc484bb5bdf62b9bf64d0a", "label": "REGENERON PHARMACEUTICALS, INC. — Full financial report (2024 Y)", "documentId": "D-dff46eb0bec646559714d5350deb456d" }, { "id": "T-124a424955cb40f4b2a3fd4a898aa490", "href": "https://app.finbar.com/go?id=T-124a424955cb40f4b2a3fd4a898aa490", "label": "REGENERON PHARMACEUTICALS, INC. — Full financial report (2024 Y)", "documentId": "D-dff46eb0bec646559714d5350deb456d" }, { "id": "P-1e0226095a2b49bfbc079a265c1b82b6", "href": "https://app.finbar.com/go?id=P-1e0226095a2b49bfbc079a265c1b82b6", "label": "REGENERON PHARMACEUTICALS, INC. — Full financial report (2024 Y)", "documentId": "D-dff46eb0bec646559714d5350deb456d" }, { "id": "P-11f3fd3688d24aa08c6307571d97e1f1", "href": "https://app.finbar.com/go?id=P-11f3fd3688d24aa08c6307571d97e1f1", "label": "REGENERON PHARMACEUTICALS, INC. — Full financial report (2024 Y)", "documentId": "D-dff46eb0bec646559714d5350deb456d" }, { "id": "P-ec6c269b8c6745369863a6c0165a85b6", "href": "https://app.finbar.com/go?id=P-ec6c269b8c6745369863a6c0165a85b6", "label": "REGENERON PHARMACEUTICALS, INC. — Full financial report (2024 Y)", "documentId": "D-dff46eb0bec646559714d5350deb456d" }, { "id": "P-a0aecc7a10f74963b2ce9c8330a7d05d", "href": "https://app.finbar.com/go?id=P-a0aecc7a10f74963b2ce9c8330a7d05d", "label": "REGENERON PHARMACEUTICALS, INC. — Press release (2024 Y)", "documentId": "D-2c5f9e182e32408e9dd091748a09dfc6" }, { "id": "P-a193603d23204e69a696d68db309612d", "href": "https://app.finbar.com/go?id=P-a193603d23204e69a696d68db309612d", "label": "REGENERON PHARMACEUTICALS, INC. — Full financial report (2024 Y)", "documentId": "D-dff46eb0bec646559714d5350deb456d" }, { "id": "P-b383fd03f62d4786a93f5e2a66a2d74d", "href": "https://app.finbar.com/go?id=P-b383fd03f62d4786a93f5e2a66a2d74d", "label": "REGENERON PHARMACEUTICALS, INC. — Full financial report (2024 Y)", "documentId": "D-dff46eb0bec646559714d5350deb456d" }, { "id": "T-6f091f9c7dc9486c81148155a7e80202", "href": "https://app.finbar.com/go?id=T-6f091f9c7dc9486c81148155a7e80202", "label": "REGENERON PHARMACEUTICALS, INC. — Full financial report (2024 Y)", "documentId": "D-dff46eb0bec646559714d5350deb456d" }, { "id": "T-84ac0a4b0a5b46379be6646a431c979c", "href": "https://app.finbar.com/go?id=T-84ac0a4b0a5b46379be6646a431c979c", "label": "REGENERON PHARMACEUTICALS, INC. — Full financial report (2024 Y)", "documentId": "D-dff46eb0bec646559714d5350deb456d" }, { "id": "P-bdd8837041e54718a1018dedbad14db0", "href": "https://app.finbar.com/go?id=P-bdd8837041e54718a1018dedbad14db0", "label": "REGENERON PHARMACEUTICALS, INC. — Full financial report (2024 Y)", "documentId": "D-dff46eb0bec646559714d5350deb456d" }, { "id": "P-d380cf0de72d4edd877335946ea6f907", "href": "https://app.finbar.com/go?id=P-d380cf0de72d4edd877335946ea6f907", "label": "REGENERON PHARMACEUTICALS, INC. — Full financial report (2024 Y)", "documentId": "D-dff46eb0bec646559714d5350deb456d" }, { "id": "T-216cefd3c4f44bb78e58e058ea26d4a5", "href": "https://app.finbar.com/go?id=T-216cefd3c4f44bb78e58e058ea26d4a5", "label": "REGENERON PHARMACEUTICALS, INC. — Full financial report (2024 Y)", "documentId": "D-dff46eb0bec646559714d5350deb456d" }, { "id": "P-c9ce9efee6ef496ca838ae8fd7680b73", "href": "https://app.finbar.com/go?id=P-c9ce9efee6ef496ca838ae8fd7680b73", "label": "REGENERON PHARMACEUTICALS, INC. — Full financial report (2023 Y)", "documentId": "D-f35f4befebab4480ba2db2f7a8c6c853" }, { "id": "P-0283b6d8812c4b4e8a48879c5bdd68c6", "href": "https://app.finbar.com/go?id=P-0283b6d8812c4b4e8a48879c5bdd68c6", "label": "REGENERON PHARMACEUTICALS, INC. — Full financial report (2024 Y)", "documentId": "D-dff46eb0bec646559714d5350deb456d" }, { "id": "P-0bcd5d0141a24e1eb020da0c8cbd1ead", "href": "https://app.finbar.com/go?id=P-0bcd5d0141a24e1eb020da0c8cbd1ead", "label": "REGENERON PHARMACEUTICALS, INC. — Full financial report (2024 Y)", "documentId": "D-dff46eb0bec646559714d5350deb456d" }, { "id": "P-ba69a7b89bca4760b7bb8fcb7bc4fd46", "href": "https://app.finbar.com/go?id=P-ba69a7b89bca4760b7bb8fcb7bc4fd46", "label": "REGENERON PHARMACEUTICALS, INC. — Full financial report (2024 Y)", "documentId": "D-dff46eb0bec646559714d5350deb456d" }, { "id": "P-51916bd12b7a4a2a9d4f729be0e594cc", "href": "https://app.finbar.com/go?id=P-51916bd12b7a4a2a9d4f729be0e594cc", "label": "REGENERON PHARMACEUTICALS, INC. — Full financial report (2024 Y)", "documentId": "D-dff46eb0bec646559714d5350deb456d" }, { "id": "P-2363abb923304d9f94252a9746605e87", "href": "https://app.finbar.com/go?id=P-2363abb923304d9f94252a9746605e87", "label": "REGENERON PHARMACEUTICALS, INC. — Full financial report (2024 Y)", "documentId": "D-dff46eb0bec646559714d5350deb456d" }, { "id": "P-3e3363d559e242baa9b4ad1f59578ae6", "href": "https://app.finbar.com/go?id=P-3e3363d559e242baa9b4ad1f59578ae6", "label": "REGENERON PHARMACEUTICALS, INC. — Full financial report (2024 Y)", "documentId": "D-dff46eb0bec646559714d5350deb456d" }, { "id": "P-f821ca0a59c94e42ae46c62681632ad2", "href": "https://app.finbar.com/go?id=P-f821ca0a59c94e42ae46c62681632ad2", "label": "REGENERON PHARMACEUTICALS, INC. — Full financial report (2024 Y)", "documentId": "D-dff46eb0bec646559714d5350deb456d" }, { "id": "T-653a90703bd44eb38a55c652cee530d4", "href": "https://app.finbar.com/go?id=T-653a90703bd44eb38a55c652cee530d4", "label": "REGENERON PHARMACEUTICALS, INC. — Full financial report (2024 Y)", "documentId": "D-dff46eb0bec646559714d5350deb456d" }, { "id": "T-500cb8cb797c4a2a9bb55ede4323943a", "href": "https://app.finbar.com/go?id=T-500cb8cb797c4a2a9bb55ede4323943a", "label": "REGENERON PHARMACEUTICALS, INC. — Full financial report (2024 Y)", "documentId": "D-dff46eb0bec646559714d5350deb456d" }, { "id": "P-688c9b6a47ab4502bcce9d4811a486bb", "href": "https://app.finbar.com/go?id=P-688c9b6a47ab4502bcce9d4811a486bb", "label": "REGENERON PHARMACEUTICALS, INC. — Full financial report (2024 Y)", "documentId": "D-dff46eb0bec646559714d5350deb456d" }, { "id": "P-304512c7a1c645088a62de029e7efe8a", "href": "https://app.finbar.com/go?id=P-304512c7a1c645088a62de029e7efe8a", "label": "REGENERON PHARMACEUTICALS, INC. — Full financial report (2024 Y)", "documentId": "D-dff46eb0bec646559714d5350deb456d" }, { "id": "P-f77933f52de041649ee8720c6a1a6116", "href": "https://app.finbar.com/go?id=P-f77933f52de041649ee8720c6a1a6116", "label": "REGENERON PHARMACEUTICALS, INC. — Full financial report (2024 Y)", "documentId": "D-dff46eb0bec646559714d5350deb456d" }, { "id": "P-3f1ee0b9ce51442981748bc5cb276e6d", "href": "https://app.finbar.com/go?id=P-3f1ee0b9ce51442981748bc5cb276e6d", "label": "REGENERON PHARMACEUTICALS, INC. — Full financial report (2024 Y)", "documentId": "D-dff46eb0bec646559714d5350deb456d" }, { "id": "P-245e0846cd974437b6bb0e3c03f0a029", "href": "https://app.finbar.com/go?id=P-245e0846cd974437b6bb0e3c03f0a029", "label": "REGENERON PHARMACEUTICALS, INC. — Full financial report (2024 Y)", "documentId": "D-dff46eb0bec646559714d5350deb456d" }, { "id": "P-efb7934e5c6b4c5d92d8dcbe283c2973", "href": "https://app.finbar.com/go?id=P-efb7934e5c6b4c5d92d8dcbe283c2973", "label": "REGENERON PHARMACEUTICALS, INC. — Full financial report (2024 Y)", "documentId": "D-dff46eb0bec646559714d5350deb456d" }, { "id": "P-dd9b7eabf30b4452b17b9c9c8473daed", "href": "https://app.finbar.com/go?id=P-dd9b7eabf30b4452b17b9c9c8473daed", "label": "REGENERON PHARMACEUTICALS, INC. — Full financial report (2024 Y)", "documentId": "D-dff46eb0bec646559714d5350deb456d" }, { "id": "P-623293aafd8e412799fd048eedbb74ce", "href": "https://app.finbar.com/go?id=P-623293aafd8e412799fd048eedbb74ce", "label": "REGENERON PHARMACEUTICALS, INC. — Full financial report (2024 Y)", "documentId": "D-dff46eb0bec646559714d5350deb456d" }, { "id": "P-6a6f1881e3fe4b35ac2dafe9a39727c1", "href": "https://app.finbar.com/go?id=P-6a6f1881e3fe4b35ac2dafe9a39727c1", "label": "REGENERON PHARMACEUTICALS, INC. — Full financial report (2024 Y)", "documentId": "D-dff46eb0bec646559714d5350deb456d" }, { "id": "P-301962b5c4be4e2f86f69867ba46a0c1", "href": "https://app.finbar.com/go?id=P-301962b5c4be4e2f86f69867ba46a0c1", "label": "REGENERON PHARMACEUTICALS, INC. — Full financial report (2024 Y)", "documentId": "D-dff46eb0bec646559714d5350deb456d" }, { "id": "https://www.regeneron.com/about/leadership/leonard-schleifer", "href": "https://www.regeneron.com/about/leadership/leonard-schleifer", "label": "www.regeneron.com" }, { "id": "https://www.regeneron.com/about/leadership/george-yancopoulos", "href": "https://www.regeneron.com/about/leadership/george-yancopoulos", "label": "www.regeneron.com" }, { "id": "P-836f4ece174444118b4062d9bd6290a3", "href": "https://app.finbar.com/go?id=P-836f4ece174444118b4062d9bd6290a3", "label": "REGENERON PHARMACEUTICALS, INC. — Full financial report (2017 Y)", "documentId": "D-da4023e7fd4947d8b1616fd324778734" }, { "id": "P-c8fe1cd47a2748a085c31166567fee79", "href": "https://app.finbar.com/go?id=P-c8fe1cd47a2748a085c31166567fee79", "label": "REGENERON PHARMACEUTICALS, INC. — Full financial report (2015 Y)", "documentId": "D-199d275aca6b47058810c65c1030f308" }, { "id": "https://investor.regeneron.com/news-releases/news-release-details/fda-approves-regenerons-arcalysttm-rilonacept-treatment/", "href": "https://investor.regeneron.com/news-releases/news-release-details/fda-approves-regenerons-arcalysttm-rilonacept-treatment/", "label": "investor.regeneron.com" }, { "id": "https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-fda-approval-eylear-aflibercept-injection/", "href": "https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-fda-approval-eylear-aflibercept-injection/", "label": "investor.regeneron.com" }, { "id": "P-75109b916d9d45e98c752dc56bd807c4", "href": "https://app.finbar.com/go?id=P-75109b916d9d45e98c752dc56bd807c4", "label": "REGENERON PHARMACEUTICALS, INC. — Full financial report (2017 Y)", "documentId": "D-da4023e7fd4947d8b1616fd324778734" }, { "id": "P-e0840901e8024776bfaa685b424252e2", "href": "https://app.finbar.com/go?id=P-e0840901e8024776bfaa685b424252e2", "label": "REGENERON PHARMACEUTICALS, INC. — Full financial report (2018 Y)", "documentId": "D-a829bb1a5410438e8f8e53ae2ac6984c" } ] }